Cartesian Therapeutics (RNAC) Change in Account Payables (2015 - 2026)
Cartesian Therapeutics (RNAC) reported Change in Account Payables of $310000.0 for Q1 2026, down 82.96% year-over-year from $1.8 million in Q1 2025, and up 133.23% quarter-over-quarter from -$933000.0 in Q4 2025.
Cartesian Therapeutics (RNAC) Change in Account Payables (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Change in Account Payables data on file, last reported at $310000.0 in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $310000.0, down 82.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$443000.0 (up 6.74% YoY), and the FY2025 annual result was $1.1 million, up 136.42% from the prior year.
- Change in Account Payables improved to $310000.0 in Q1 2026 per RNAC's latest filing, from -$933000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $2.8 million in Q4 2023 and troughed at -$2.4 million in Q3 2024.
- A 5-year average of $80882.4 and a median of $85000.0 in 2023 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables surged 4050.0% in 2023, then tumbled 2923.53% in 2024.
- A 5-year view of Change in Account Payables shows it stood at $102000.0 in 2022, then soared by 2643.14% to $2.8 million in 2023, then tumbled by 108.47% to -$237000.0 in 2024, then slumped by 293.67% to -$933000.0 in 2025, then surged by 133.23% to $310000.0 in 2026.
- Business Quant data shows RNAC's Change in Account Payables at $310000.0 in Q1 2026, -$933000.0 in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | 310,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 310,000.00 |
| Mar 31, 2026 | 310,000.00 |
| Dec 31, 2025 | -933,000.00 |
| Dec 31, 2025 | -933,000.00 |
| Sep 30, 2025 | 1.77 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | -1.59 Mn |
| Jun 30, 2025 | -1.59 Mn |
| Mar 31, 2025 | 1.82 Mn |
| Mar 31, 2025 | 1.82 Mn |
| Dec 31, 2024 | -237,000.00 |
| Dec 31, 2024 | -237,000.00 |
| Sep 30, 2024 | -2.40 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Jun 30, 2024 | 343,000.00 |
| Jun 30, 2024 | 343,000.00 |
| Mar 31, 2024 | -633,000.00 |
| Mar 31, 2024 | -633,000.00 |
| Dec 31, 2023 | 2.80 Mn |
| Dec 31, 2023 | 2.80 Mn |